Study of MRG003 for small cell lung cancer that has returned
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug, MRG003, for people with a type of lung cancer called small cell lung cancer that has spread or come back after earlier treatment. The goal is to see if this drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with small cell lung cancer that has spread to other parts of the body or has come back after treatment.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (up and about, capable of light work).
- You have not had cancer treatment recently, and your body is functioning well enough per study checks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
This study tests a new drug called MRG003 against two other treatments (cetuximab or methotrexate) for people with a type of head and neck cancer that has come back or spread and has not responded to standard treatments. The goal is to see if the new drug can better control the cancer and improve outcomes.
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
This study tests an investigational drug called BL0020 for people whose non-small cell lung cancer has changed into small cell lung cancer after treatment with EGFR inhibitors. The goal is to see if BL0020 can help control the cancer.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
Hear when a new Relapsed Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.